Therapix Biosciences Ltd.
TRPX
TRPX was delisted on the 1st of July, 2020.
6 hedge funds and large institutions have $212K invested in Therapix Biosciences Ltd. in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
31% more capital invested
Capital invested by funds: $162K → $212K (+$50K)
0% more funds holding
Funds holding: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$240K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$62K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$17.6K |
| 4 |
Barclays
London,
United Kingdom
|
+$3.95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
-$406 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $160K | +$240K | +41,448 | +525% |
|
|
OAM
2
Oxford Asset Management
Oxford,
United Kingdom
| $35K | +$62K | +10,709 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $15K | +$17.6K | +3,030 | +192% |
|
|
4
Barclays
London,
United Kingdom
| $2K | +$3.95K | +681 | New |
|
|
IA
5
IFP Advisors
Tampa,
Florida
| – | -$406 | -70 | -78% |
|
TRPX Hedge Fund Activity: Q4 2018 in Review
6 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Therapix Biosciences Ltd. (TRPX) for Q4 2018, worth a combined $212K — up 31% from $162K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new TRPX positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $240K. The largest seller was IFP Advisors, cutting an estimated $406.
- 6 institutional investors held Therapix Biosciences Ltd. (TRPX) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $212K of Therapix Biosciences Ltd. stock for Q4 2018, up 31% quarter-over-quarter.
- 2 funds opened new Therapix Biosciences Ltd. positions in Q4 2018 and 1 closed out, a net change of +1 holder.
- The largest Therapix Biosciences Ltd. buyer in Q4 2018 was Morgan Stanley, an estimated $240K added.
- The largest Therapix Biosciences Ltd. seller in Q4 2018 was IFP Advisors, an estimated $406 sold.
Based on aggregated 13F filings for Q4 2018.